Efficacy and Safety of [

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

1. Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis.European journal of nuclear medicine and molecular imaging · 2026
   Pooled it
2. Beyond [BMC cancer · 2026
   Pooled it
3. Efficacy and Safety ofFrontiers in oncology · 2022
   Pooled it
4. [International journal of molecular sciences · 2026
   Article
5. PSMA Theranostics in Prostate Cancer and Beyond: Current and Future Perspectives.Cancers · 2025
   Review
6. Clinical perspective on targeted alpha therapy usingAnnals of nuclear medicine · 2025
   Review
7. Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
8. Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025
   Review
9. Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer.PET clinics · 2025
   Review
10. Current status of radionuclide therapies in metastatic castration-resistant prostate cancer.Therapeutic advances in medical oncology · 2025
    Review
11. Pilot experience of [Theranostics · 2025
    Observational
12. Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review.Frontiers in medicine · 2025
    Article
13. PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2024
    Article
14. Efficacy and safety of rechallenge [European journal of nuclear medicine and molecular imaging · 2024
    Observational
15. Analysis of Molecular Imaging Biomarkers Derived from [Cancers · 2024
    Article
16. DNA Damage and Repair in PBMCs after Internal Ex Vivo Irradiation with [International journal of molecular sciences · 2024
    Article
17. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
18. Design ofAnnals of translational medicine · 2024
    Review
19. Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.Current oncology reports · 2023
    Review
20. Tandem Isotope Therapy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

9 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as